Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Sorrento Therapeutics outlicenses Chinese rights to anti-PD-L1 antibody

Oct. 7, 2014

Oxford BioTherapeutics and Berlin Chemie/Menarini select second anticancer antibody-drug conjugate

Oct. 6, 2014

Phase I trial of lirilumab in combination with elotuzumab begins

Oct. 6, 2014

OncoMed and Bayer select small-molecule Wnt pathway inhibitor for preclinical development

Oct. 3, 2014

Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination trial

Oct. 3, 2014

Helix BioPharma reports interim data from phase I/II trial of L-DOS-47

Oct. 2, 2014

Bristol-Myers Squibb provides milestone update for Opdivo

Sep. 30, 2014

EMA committee recommends European approval of Cyramza

Sep. 29, 2014

FDA grants orphan drug status to IMM-101 for pancreatic cancer

Sep. 26, 2014

FDA grants orphan drug designation to MabVax Therapeutics' neuroblastoma vaccine

Sep. 26, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...